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Background. Kenyan antiretroviral (ART) guidelines encourage treatment buddies (TBy) to maximize treatment adherence. This
study examined the effect of TBys on clinic attendance in men and women on ART. Methods. This retrospective cohort study
included all adult patients initiating ART from August 2007 to December 2011 at four health facilities in Kenya. Data were
abstracted from electronic medical records and analyzed using Poisson regression. Results. Of 2,430 patients, 2,199 (91%) had a
TBy. Relationship between TBy and clinic attendance differed in females and males (interaction 𝑝 = 0.09). After demographic and
clinic factor adjustment, females with a TBy were 28%more likely to adhere to all appointments than those without (adjusted aRR =
1.28; 95% CI 1.08–1.53), whereas males were nomore likely to adhere (aRR = 1.01; 95% CI 0.76–1.32). Males reported partner/spouse
(33%) or brother (11%) as the TBy while females reported sister (17%), partner/spouse (14%), or another family member (12%).
Multivariable analysis found no association between clinic attendance and TBy relationship in either gender. Conclusion. Clinic
attendance was higher among women with TBys but not men. Results support TBys to help women achieve ART success; alternate
strategies to bolster TBy benefits are needed for men.
1. Introduction
In 2013, over 7.6millionHIV-infectedAfricanswere receiving
antiretroviral drugs [1], including approximately 650,000 in
Kenya [2]. Regular clinic attendance is essential for monitor-
ing and responding to disease progression in this population;
providing prophylactic medications for opportunistic infec-
tions; sustaining drug adherence; and evaluating patients
for drug toxicities. Patients who miss visits are at increased
risk for interruptions in antiretroviral therapy (ART), poorer
immunological and virological outcomes, and higher rates
of loss to follow-up and mortality [3–9]. They are also more
likely to experience HIV progression [10], viral resistance to
drugs [7], and treatment failure [7]. Appointment adherence
early in antiretroviral treatment may be particularly critical
to long-term outcomes because side effects are more likely
to occur when patients are initiated on a regimen [11, 12].
Although high clinic attendance has been achieved in some
resource-limited settings [13], there remains an urgent need
for practical interventions to improve attendance to avoid
drug resistance and treatment failure.
Clinic attendance may be influenced by patient social
contexts and interpersonal relations with family mem-
bers and within communities. Social support systems can
help patients overcome structural and financial barriers
to accessing care, provide a context for patients to dis-
cuss concerns about their diagnosis and treatment, and
buffer against community stigma [14]. Studies have found
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patients with social support are less likely to miss a clinic
visit [15] and report an easier time reengaging in care
after an appointment has been missed [16]. One strategy
to utilize the benefits of social support recommended by
Kenya’s National AIDS and STI Control Program (NASCOP)
is engagement of a patient-nominated treatment buddy
(TBy), an individual, usually a trusted family member or
friend, who commits to supporting the patient on ART.
The TBy may accompany the patient to the clinic and
help with treatment adherence [17, 18], provide lay counsel
and encouragement, and support patients in establishing
healthy behaviors, such as curbing drug and alcohol use
[19].
Previous studies of TBys have focused largely on ART
adherence andHIVoutcomes, withmixed results. A prospec-
tive cohort study among patients initiating ART at public
facilities in South Africa found higher odds of treatment
success (defined as viral load < 400 copies/mL, CD4 ≥ 200
cells/mm3) at six months, one year, and two years after
ART initiation among patients with TBys [20]. However,
a randomized controlled trial (RCT) also in South Africa
showed no difference in CD4 cell count or viral load at one or
two years after ART initiation among patients who received
directly observed ART (DOT-ART) by a TBy compared to
a control group who self-administered ART [21], although
survivorship was unexplainably better in the TBy DOT-
ART group. A RCT in Nigeria found a significantly higher
proportion of those in the TBy arm maintained timely ART
drug pickup but showed no durable effect on CD4 cell count
or mortality [22].
To our knowledge, only one other study has evalu-
ated effects of a TBy on clinic attendance. A recent RCT
of a TBy intervention among 174 patients attending an
HIV clinic in Uganda found no difference in clinic atten-
dance during the 28-week follow-up period [23]. Our study
sought to reevaluate this finding within the context of HIV
care in Kenya and consider the impact of the interven-
tion separately for men and women. There is considerable
evidence for gender differences in HIV health behaviors
among African men and women: men have lower compli-
ance with antiretroviral therapy [24, 25] and higher rates
of attrition from care [25, 26] than women, which in
turn contribute to their poorer immunological response to
treatment and elevated risk of mortality [25, 27]. Although
these disparities remain poorly understood, it appears that
existing strategies to promote retention and adherence have
been less successful in men than women. Based on these
findings we sought to determine (1) the effect of TBy
on clinic attendance within the first six months on ART
in a cohort of HIV-infected male and female patients in
Kenya and (2) whether this effect differs between men and
women. In addition, because qualitative studies have also
highlighted the influence of the relationship between TBys
and patients [28, 29], we also sought to characterize the types
of relatives and patients chosen as a TBy and explore whether
choice of relative impacted clinic attendance in our study
population.
2. Materials and Methods
2.1. Study Design and Participants. This was a retrospective
cohort study of HIV-infected adult patients ≥15 years of age
initiating ART between August 1, 2007, and December 23,
2011. The study targeted four Family AIDS Care & Education
Services (FACES) supported facilities (PandiPieri, Lumumba,
Family Health Options Kenya (FHOK), and Tuungane) in
Kisumu County, where the prevalence of HIV (19%) is more
than three times the national average for Kenya (6%) [30].
FHOK specializes in treatment of female sex workers, Tuun-
gane serves pediatric and adolescent clients, and PandiPieri
and Lumumba are high volume sites enrolling patients of all
ages. Only patients engaged into HIV care on or after July 23,
2007 (following onset of electronic medical records capture),
who had documentedwhether or not they had aTBy andwho
did not discontinue from care during the six-month post-
ART follow-up were included in the study sample. This was
done to establish the effect of the TBy on clinic attendance
separate from the effect of the TBy on retention in care.
Eligibility guidelines for ART initiation were revised during
the study period fromaCD4 count of≤200 cells/mm3 to≤350
cells/mm3 in 2011 following a change in national guidelines
[31].
2.2. Pre-ART Clinic Procedures. Prior to ART initiation, the
patient is counseled to disclose his/her status to one or
two trusted individuals who can support his/her treatment,
typically a partner, parent, daughter, sister, brother, friend,
or neighbor. The patient brings the TBy to the clinic to
participate in the pre-ART adherence counseling process, a
series of three counseling and education sessions that cover
HIV transmission and risk factors; disease progression and
CD4 monitoring; purpose, benefits, and importance of ART
medication and adherence; consequences of poor adherence;
treatment schedule and reminder systems; and disclosure and
positive living. TBys provide ongoing support for positive
living and medication adherence. Patients are expected to
notify the facility if there is a TBy change.
2.3. Clinic Attendance. In Kenya, a patient’s first six-
month observation period following ART initiation typically
includes a first clinic visit two to four weeks after ART
initiation and monthly thereafter. Providers assess health
status, adherence, drug regimen tolerance, and toxicity and
modify the ARV regimen if needed. Patients are provided
withARV refills to last themuntil their next clinic visit, which
is scheduled that day. A patient may also come to the clinic
between scheduled visits as needed. TBys may attend clinic
appointments with the patient or may come in the patient’s
place to pick up the drugs.
2.4. Data Collection. Patient demographic factors, TBy sta-
tus, and appointment adherence data were extracted from
medical encounter forms collected during routine patient
care and entered into an open source electronic medical
records system database (OpenMRS system version 1.8.3).
For the majority of patients (2416/2430), TBy details were
extracted from the pre-ART adherence counseling form
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completed immediately prior to ART initiation. Another 14
patients whose TBy details could not be ascertained from
the pre-ART adherence counseling form but who indicated
having a TBy at the time of engagement into care were coded
as having aTBy. Clinic appointment adherencewas defined as
completing all scheduled clinic appointments within the first
six months on ART. An appointment was deemed completed
if the patient was seen on or within three business days after
the scheduled return date or had appeared in the clinic prior
to the scheduled return date.
2.5. Measures and Statistical Analysis. The outcome was the
proportion of patients who attended all clinic visits within
the first six months on ART. TBy was operationalized as
dichotomous for primary analyses (1 = having TBy; 0 =
having no TBy) and categorical for a secondary analysis
that examined clinic attendance by relationship with TBy
(1 = having no TBy; 2 = partner is the TBy; 3 = another
family member or friend is the TBy). Chi-square tests
were performed to assess differences in demographic and
clinical characteristics by TBy status. Multivariable Poisson
regression with robust standard errors was used to obtain
adjusted relative risks. An initial regression model with
terms for TBy (dichotomous), gender, and their interaction
found a significant difference in male and female response to
treatment support at 𝑝 < 0.20; thus we decided to develop
separate models for males and females. Patient’s age, marital
status, year initiated on ART, CD4 count, and clinic site
were included in each multivariable model on prior belief
that they might confound the TBy relationship with clinic
attendance. Educational status, WHO HIV clinical stage,
and months from engagement in care until ART initiation
were maintained in the multivariable models if associated
with clinic attendance at 𝑝 < 0.20 on bivariable analysis.
Educational status did not meet this criterion in either men
or women and was omitted from multivariable models. Data
was analyzed using SAS version 9.3 (SAS Institute, Cary, NC).
2.6. Ethical Statement. Use of the program data for research
was approved by the Kenya Medical Research Institute
(KEMRI) Ethical Review Committee and the Committee
on Human Research (11-05348) at the University of Cali-
fornia San Francisco. All patient data were stripped of any
identifying details and identified only by a unique patient
number.
3. Results and Discussion
3.1. Sample Characteristics. Of 2,430 patients who met inclu-
sion eligibility requirements in this study, 2199 (90.5%) had
a TBy (Table 1). The majority of patients were female, had
no more than a primary school education, and were married
or partnered. Over 40% had been engaged in care for less
than a month when initiated on ART and most had a CD4
cell count of <200 (prior to change in Kenyan National
Guidelines) or <350 cells/mm3 at time of ART initiation. A
greater proportion of males had a TBy than females, and
a greater proportion of married/partnered patients had a
TBy than single patients. Patients with a TBy were older.
Proportion with a TBy was higher among patients at WHO
stages 3 and 4 at initiation (Table 1).
On univariate analysis, patients with a TBy were more
likely to achieve consistent appointment adherence (Table 2).
The majority (60%) of patients with a TBy met all sched-
uled appointments during the six-month follow-up period,
compared to just under half (49%) of those without a TBy
[RR = 1.23; 95% CI 1.07–1.41]. The relationship between TBy
and clinic attendance differed by gender (interaction 𝑝 =
0.09). Equal proportions ofmenwith andwithout a treatment
buddy adhered to their visit schedule (57% versus 57%; RR =
1.00; 0.76–1.31). In females, 61% with a TBy consistently met
scheduled appointments versus 47%without a TBy (RR= 1.31;
95% CI 1.11–1.53).
After adjusting for age, marital status, year initiated ART,
months from engagement in care to ART initiation, CD4
count, WHO stage, and clinic site, females with a TBy were
nearly 30% more likely to meet all scheduled appointments
during the appointment follow-up period than those without
one (adjusted aRR = 1.28; 95% CI 1.08–1.53; Table 3). Clinic
attendance showed a positive association with increasing
age, with adjusted risk significantly higher among females
aged 30–44 than females aged 15–29. Being in a partnership,
belonging to a more recent ART initiation cohort (2011
versus 2007, 2008, or 2009), and initiating ART at an earlier
clinical WHO stage were all independently associated with
better clinic attendance in females. Females seen at Tuungane,
PandiPieri, or FHOK were less likely to have adhered to the
appointment schedule than those at Lumumba.
As with the univariate results, TBy showed no association
with clinic attendance in males after adjustment for age,
marital status, year initiated ART, months from engagement
in care to ART initiation, CD4 count, WHO stage, and clinic
site (aRR = 1.01; 95% CI 0.76–1.32; Table 3). Clinic attendance
was lower in males who initiated ART at WHO stages 3 and
4 compared to WHO stage 1. Clinic attendance was lower
among males at Tuungane or PandiPieri compared to males
at Lumumba.
3.2. Treatment Buddy Relationship to Patient. Type of rela-
tionship with the TBy differed by patient gender (𝑝 <
0.0001; data not shown). Males most commonly reported
a partner/spouse (33%), brother (11%), or another family
member (7%) as their TBy. Females more often reported the
TBy to be a sister (17%), followed by the partner/spouse (14%)
or another family member (12%). Relationship with TBy was
missing for 28% of males (𝑛 = 217) and 28% of females (𝑛 =
397). On crude analysis, females whose TBy was a partner or
spouse were more likely to have attended all appointments
during the follow-up period than women whose TBy was
another family member or friend (70% versus 61%; Table 4).
However, after adjustment for age, marital status, year ART
initiated, CD4 count, clinic site, months from engagement in
care to ART initiation, andWHO stage, there was no longer a
significant difference in clinic attendance by relationshipwith
TBy among females (aRR = 1.01; 95% CI 0.90–1.14). Similarly,
on crude analysis more males with a partner or spouse as the
TBymet their appointment schedule than those with another
family member or friend (62% versus 52%), but there was
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Table 1: Sample characteristics (𝑛 = 2430)∗.
Characteristics TBy (𝑛 = 2199) No TBy (𝑛 = 231) 𝑝 value∗∗
Gender <0.0001
Male 770 (94.8) 42 (5.2)
Female 1429 (88.3) 189 (11.7)
Age (years; enrollment), median (IQR) 32 (27–39) 30 (25–35) <0.0001
15–29 852 (88.3) 113 (11.7)
30–44 1038 (90.7) 107 (9.3)
45+ 309 (96.6) 11 (3.4)
Education level (enrollment) 0.05
None 57 (98.3) 1 (1.7)
Primary 1118 (91.2) 108 (8.8)
Secondary 665 (89.4) 79 (10.6)
College 164 (93.7) 11 (6.3)
Missing 195 (85.9) 32 (14.1)
Marital status (enrollment) <0.0001
Single 894 (87.9) 123 (12.1)
Partnered 1076 (93.1) 80 (6.9)
Missing 229 (89.1) 28 (10.9)
Children in household (enrollment) 0.11
0 469 (90.9) 47 (9.1)
1 447 (91.4) 42 (8.6)
2 457 (88.1) 62 (12.0)
3+ 563 (92.1) 48 (7.9)
Missing 263 (89.2) 32 (10.9)
Year ART initiated <0.0001
2007 31 (79.5) 8 (20.5)
2008 242 (80.9) 57 (19.1)
2009 513 (91.3) 49 (8.7)
2010 749 (92.5) 61 (7.5)
2011 664 (92.2) 56 (7.8)
Months from enrollment to ART initiation, median (IQR) 1 (0–3) 1 (0–6) 0.03
<1 964 (91.7) 87 (8.3)
1-2 530 (91.7) 48 (8.3)
2-3 131 (86.2) 21 (13.8)
>3 574 (88.4) 75 (11.6)
CD4 count (cells/mm3; ART initiation), median (IQR)† 180 (82–260) 189 (113–280) 0.52
>350 155 (88.6) 20 (11.4)
200–350 797 (90.2) 87 (9.8)
<200 1207 (91.0) 119 (9.0)
WHO stage (ART initiation)† 0.03
1 526 (88.9) 66 (11.2)
2 697 (88.7) 89 (11.3)
3 809 (92.7) 64 (7.3)
4 156 (92.9) 12 (7.1)
Clinic site <0.0001
Lumumba 993 (90.8) 101 (9.2)
Tuungane 73 (97.3) 2 (2.7)
PandiPieri 1011 (94.9) 54 (5.1)
FHOK 122 (62.2) 74 (37.8)
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Table 1: Continued.
Characteristics TBy (𝑛 = 2199) No TBy (𝑛 = 231) 𝑝 value∗∗
Retention during first 6 months on ART 0.001
Missed ≥1 visits 890 (88.2) 119 (11.8)
Missed no visits 1309 (92.1) 112 (7.9)
∗
𝑛 (%) shown unless otherwise indicated.
∗∗Significance tests based on nonmissing values.
†There were missing data for the following predictors:
CD4 count: 45 patients; 40 with treatment buddy and 5 without treatment buddy.
WHO stage: 10 patients, all with treatment buddy.
Table 2: Unadjusted relative risks for factors associated with clinic attendance during the first six months on ART, overall, and by gender.
Predictor Total (𝑛 = 2430) Male (𝑛 = 812) Female (𝑛 = 1618)
𝑛 % attended RR (95% CI) 𝑛 % attended RR (95% CI) 𝑛 % attended RR (95% CI)
Has treatment buddy
Yes 1309 59.5 1.23 (1.07–1.41) 770 57.1 1.00 (0.76–1.31) 1429 60.8 1.31 (1.11–1.53)
No 112 48.5 REF 42 57.1 REF 189 46.6 REF
Treatment buddy × gender interaction 𝑝 value = 0.09
no significance difference in clinic attendance by relationship
type with the TBy after multivariable adjustment (aRR = 1.05;
95% CI 0.89–1.24).
3.3. Discussion. In this study we found better clinic atten-
dance among women with a TBy but not men. Women
with a TBy were nearly 30% more likely to have kept all
appointments within the first six months on therapy than
womenwithout a TBy. Clinic attendancewas not significantly
different in men with or without a TBy.
For women, these findings have promising implications.
Clinically, consistent attendance is essential for timely ART
delivery and monitoring for toxicities and treatment failure;
preventing ART interruptions is crucial because treatment
lapses can result in drug resistance and increased mortality
risk [32]. Although we could not verify that ARV adherence
or clinical outcomes were better in women with more consis-
tent attendance, because the sites participating in this study
follow a protocol of prescribing ART refills to last until the
next visit, missed visits represented likely gaps in treatment,
placing patients at risk for poorer HIV outcomes [5] and
higher risk of drug resistance [7].
For men, our finding of no TBy effect on attendance is
of special concern because men show a broader pattern of
poorer engagement and retention [33], are known to delay
HIV testing and enrollment in care compared to women,
and are more likely to lapse in ARV adherence and drop
out of care [32, 34]. While the reasons for these disparities
require further study, recent qualitative work by Chikovore
et al. highlights the importance of social role definitions
which place greater responsibility for family income gen-
eration on men [35]. Within a context of job scarcity and
constant insecurity, pressure to find and maintain work may
lead men to relegate health considerations. A retrospective
analysis of clinical data from HIV care facilities in Kenya
also found work commitments the most common reason for
missed visits among men, while women were more likely
to report family commitments [34]. With respect to our
own findings, we speculate that TBys may be better able to
help with competing childcare and household obligations
than occupational commitments or costs of lost wages and
contracts faced by workers who take time off.
Gender differences in social norms and economic stand-
ing may also influence how men and women relate to the
TBy in other ways. Norms of masculinity that emphasize
resilience and self-reliance discourage African men from
seeking help from others when needed [36]. At the same
time, the lower economic status of African women may lead
to greater dependency on community support to surmount
hardships and therefore indirectly promote better attendance
behavior. A recent ethnographic study conducted in Nigeria,
Tanzania, and Uganda found that HIV patients adhere to
treatment guidelines to fulfill the expectations of members
of their social network who provide financial or practical
support [37]. In resource-poor environments, patients must
borrow money from friends and family for food, transport
to clinic, and other needs. Adherence demonstrates that the
patient will use the investment responsibly and can be relied
uponwith future resources for care-related or other expenses.
As such, wemight expect TBys to exert greater influence over
more marginal and economically vulnerable patients.
The protocols followed at the clinics included in this study
allowed patients to self-select the TBy from among trusted
family and friends. Treatment buddies participated in pre-
ART preparatory education and counseling sessions with the
patient and supported patients with medication reminders.
TBys were also encouraged to attend clinic appointments
with patients if possible and support patients with pickup of
ART refills when necessary and feasible. To our knowledge,
only one other study has evaluated a similar patient self-
selected TBy intervention on clinic attendance, a recent RCT
led by Kunutsor et al. among 174 patients onART at a hospital
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Table 3: Adjusted relative risks for factors associated with clinic attendance during the first six months on ART, by gender.
Predictor Male (𝑛 = 716) Female (𝑛 = 1405)
𝑛 % attended aRR 95% CI 𝑝 value 𝑛 % attended aRR 95% CI 𝑝 value
Has treatment buddy
Yes 679 57.6 1.01 0.76–1.32 0.97 1243 60.6 1.28 1.08–1.53 0.005
No 37 59.5 REF 162 45.1 REF
Age
15–29 173 56.7 REF 681 54.9 REF
30–44 394 56.6 0.99 0.85–1.15 0.90 599 62.4 1.12 1.03–1.22 0.01
45+ 149 61.7 1.05 0.87–1.25 0.62 125 62.4 1.14 0.98–1.33 0.08
Marital status
Single 191 53.9 REF 798 54.0 REF
Partnered 525 59.1 1.02 0.89–1.18 0.75 607 65.1 1.10 1.01–1.20 0.04
Year ART initiated
2007 6 16.7 0.20 0.03–1.24 0.08 26 42.3 0.62 0.39–0.99 0.04
2008 78 59.0 0.83 0.66–1.03 0.09 151 54.3 0.80 0.68–0.94 0.007
2009 163 60.7 0.97 0.82–1.14 0.71 318 53.8 0.83 0.73–0.94 0.003
2010 245 57.1 0.90 0.77–1.05 0.17 479 61.0 0.94 0.85–1.04 0.24
2011 224 56.7 REF 431 62.7 REF
Months from engagement in care
to ART initiation
<1 354 52.5 REF 581 58.5 REF
1-2 188 60.6 1.07 0.92–1.23 0.37 315 55.9 0.92 0.82–1.04 0.18
2-3 42 61.9 1.12 0.85–1.48 0.40 96 51.0 0.88 0.72–1.08 0.21
>3 132 65.9 1.12 0.94–1.32 0.20 413 63.2 1.04 0.93–1.16 0.45
CD4 count
>350 38 65.8 1.09 0.84–1.40 0.51 115 56.5 0.92 0.77–1.09 0.32
200–350 214 63.1 1.04 0.90–1.20 0.61 565 63.4 1.05 0.95–1.16 0.36
<200 464 54.5 REF 725 55.6 REF
WHO stage
1 151 67.6 REF 365 66.0 REF
2 194 61.9 0.93 0.80–1.09 0.36 506 58.1 0.91 0.83–1.01 0.09
3 308 51.3 0.80 0.69–0.93 0.003 454 57.1 0.91 0.81–1.01 0.08
4 62 51.6 0.74 0.57–0.96 0.03 80 40.0 0.65 0.49–0.85 0.002
Clinic site
Lumumba 345 72.5 REF 577 71.4 REF
Tuungane 22 45.5 0.58 0.36–0.92 0.02 41 31.7 0.44 0.28–0.69 0.0003
PandiPieri 349 43.8 0.58 0.51–0.67 <0.0001 610 52.3 0.69 0.63–0.76 <0.0001
FHOK na na na na na 177 46.3 0.68 0.57–0.81 <0.0001




𝑛 % attended RR (95% CI)(𝑛 = 595)
aRR (95% CI)∗






Partner/spouse 250 62.4 1.18 (1.02–1.36) 1.05 (0.89–1.24) 198 69.7 1.14 (1.03–1.27) 1.01 (0.90–1.14)
Other 303 51.8 REF REF 834 60.9 REF REF
None 42 57.1 1.08 (0.82–1.44) 1.03 (0.77–1.37) 189 46.6 0.76 (0.65–0.90) 0.75 (0.62–0.90)
∗Adjusted for age, marital status, year ART initiated, CD4 count, clinic site, months from engagement in care to ART initiation, and WHO stage.
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in Uganda [23]. That study, which pooled together results
for men and women, found a weak but not statistically
significant trend towards better clinic attendance in the TBy
group compared to the standard-of-care group. It may be that
the larger sample included in this study allowed for better
detection of differences between groups or that the decision
to stratify by gender highlighted an effect among women
masked in the earlier trial.
Previous research has shown that patients and providers
choose treatment buddies who are confidantes and able to
influence health-related decision-making [25, 28, 37]. Trust,
geographic proximity to the TBy, emotional availability,
reciprocity, and material resources are all important features
of the treatment buddy-patient relationship [29]. In our
study, most patients selected a family member to serve as
a TBy. Women most often chose a sister, perhaps because
they perceived sisters to be more supportive than other
family members [38]. Men were more than twice as likely
to report the partner as the TBy than women, probably
because they faced less risk of partner violence or stigma.
Relationship type did not however appear to influence the
effect of the TBy on clinic attendance in either gender. For
women, clinic attendance was higher whether they chose
the partner or another family member or friend. In men,
clinic attendance was not significantly different whether
they chose the partner, another family member or friend,
or no TBy.
Strengths of our study include a large, representative
cohort of patients at multiple HIV care settings in Kenya.
This is the first study to our knowledge to examine the
effectiveness of TBys as an intervention in Kenya and the
only large-scale study to examine type of relationship to
the TBy among HIV patients in sub-Saharan Africa. A
study limitation was that it was based on observational
data and may be subject to unmeasured confounding. In
particular, because of the self-nominated nature of the TBy
intervention at FACES-supported clinics, patients with a TBy
may have generally stronger social connections and greater
support within their social network than those without a
TBy. Thus the TBy may serve as a marker for social capital.
Patients initiated on ART without a TBy also reflect an
unusual exception to Kenyan guidelines that encourage the
selection of a TBy and may therefore differ from the general
population of new patients on ART. For example, they may
be more disadvantaged or have more clinically advanced
illness. Nevertheless, we were able to control for a number
of sociodemographic and disease markers to help account
for some of these differences. A second limitation of this
study was that TBy status could only be ascertained for the
48% of patients initiated on ART during the study period
for whom pre-ART adherence counseling data was available
in the administrative database. Third, we were not able to
directly associate clinic attendance with ARV adherence or
clinical outcomes. However, the relationship between clinic
attendance andARTadherence and outcomes has been firmly
established [3–5, 8]. Finally, we only examined attendance
patterns during the first six months on ART. One- and two-
year follow-up are needed to assess longer-term durability of
our findings.
4. Conclusions
In summary, clinic attendance was higher during the first six
months of ART among women with TBys but not men.These
results support TBys to help women achieve ART success
in resource-poor settings; alternate strategies to bolster TBy
benefits are needed for men. Specialized trainings for TBys
and caregiver support groupsmay further enhance the impact
of TBys on adherence and health outcomes for all patients on
ART.
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